Index
RUT
Market Cap
630.80M
Enterprise Value
-294.54M
Income
-99.85M
Sales
23.29M
Book/sh
14.90
Cash/sh
15.46
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
109
IPO
Jun 11, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
27.08
P/B
0.69
P/C
0.67
P/FCF
-
EV/EBITDA
-
EV/Sales
-12.65
Quick Ratio
17.69
Current Ratio
17.69
Debt/Eq
0.02
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
-1.59
EPS next Y
-2.54
EPS next Q
-0.52
EPS this Y
10.62%
EPS next Y
-55.25%
EPS next 5Y
-19.81%
EPS past 3/5Y
-6.44% -62.26%
Sales past 3/5Y
5.11% -
EPS Y/Y TTM
4.85%
Sales Y/Y TTM
132.89%
EPS Q/Q
12.78%
Sales Q/Q
-7.11%
Insider Own
5.41%
Insider Trans
-0.12%
Inst Own
96.94%
Inst Trans
1.81%
ROA
-9.94%
ROE
-10.58%
ROIC
-10.74%
Gross Margin
92.02%
Oper. Margin
-599.26%
Profit Margin
-428.74%
SMA20
-31.30%
SMA50
-36.54%
SMA200
-32.66%
Trades
Shs Outstand
61.17M
Shs Float
57.87M
52W High
35.34 -70.83%
52W Low
10.50 -1.81%
Volatility
5.07% 7.69%
ATR (14)
1.06
RSI (14)
26.01
Beta
2.52
Rel Volume
1.03
Avg Volume
952.53K
Volume
976,346
Perf Week
-16.79%
Perf Month
-40.06%
Perf Quarter
-40.34%
Perf Half Y
-28.40%
Perf YTD
-25.29%
Perf Year
-64.47%
Perf 3Y
18.78%
Perf 5Y
-45.77%
Perf 10Y
-
Prev Close
10.71
Price
10.31
Change %
-3.73%
Analysts 14 incl. previous ratings
Rating Distribution 10 Buy · 3 Hold · 1 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Nov 12, 2026 Downgrade W Wolfe Research
Outperform → Peer Perform Aug 24, 2026 Upgrade W Wolfe Research
Peer Perform → Outperform $23 +123.1% Apr 20, 2026 Downgrade B Barclays
Overweight → Underweight $14 +35.8% Apr 15, 2026 Downgrade U UBS
Buy → Neutral $15 +45.5% Nov 18, 2025 Initiated W Wolfe Research
Peer Perform Sep 17, 2025 Initiated B Barclays
Overweight $47 +355.9% Sep 10, 2025 Initiated T Truist
Buy $100 +869.9% Sep 10, 2025 Initiated S Stifel
Buy $45 +336.5% Sep 04, 2025 Initiated G Guggenheim
Buy $72 +598.4% Aug 19, 2025 Initiated P Piper Sandler
Overweight $42 +307.4% Jul 11, 2025 Initiated R Raymond James
Outperform $65 +530.5% Dec 03, 2024 Reiterated H H.C. Wainwright
Buy $63 → $70 +579.0% Dec 03, 2024 Reiterated B BTIG Research
Buy $82 → $100 +869.9% Nov 22, 2024 Initiated L Leerink Partners
Outperform $79 +666.2% Oct 24, 2024 Initiated U UBS
Buy $69 +569.3% Sep 06, 2024 Initiated S Stifel
Buy $70 +579.0% May 30, 2024 Initiated B Scotiabank
Sector Perform $47 +355.9% Mar 21, 2024 Initiated B BTIG Research
Buy $62 +501.4% Mar 20, 2024 Initiated C Cantor Fitzgerald
Overweight $100 +869.9% Apr 06, 2023 Initiated W Wedbush
Outperform $24 +132.8%
Show Previous Ratings
Nov-09-26 07:30AM
Nov-05-26 03:02PM
Nov-02-26 03:02PM
Sep-14-26 08:00AM
Aug-24-26 09:54AM
04:02PM
Loading…
Aug-06-26 04:02PM
Jul-02-26 06:40PM
May-28-26 06:33PM
12:53PM
May-07-26 04:01PM
Apr-28-26 05:57AM
Apr-27-26 04:01PM
Apr-17-26 06:04AM
Apr-16-26 04:01PM
Apr-01-26 08:01AM
02:56AM
Loading…
Mar-02-26 02:56AM
Feb-26-26 04:01PM
Feb-19-26 09:59AM
Feb-17-26 07:00AM
Feb-16-26 09:40AM
Feb-03-26 09:55AM
Jan-26-26 07:00AM
Jan-23-26 07:18AM
Jan-22-26 02:02PM
01:01PM
(Pharmaceutical Technology)
07:00AM
07:00AM
Dec-27-25 07:43AM
Dec-23-25 04:05PM
Dec-12-25 07:30AM
04:14PM
Loading…
Dec-02-25 04:14PM
(Investor's Business Daily)
-53.34%
+7.88%
09:53AM
08:30AM
05:15AM
Dec-01-25 04:05PM
Nov-24-25 08:00AM
Nov-16-25 10:13PM
Nov-06-25 06:10PM
04:01PM
Oct-30-25 05:53AM
Oct-29-25 07:46AM
07:05AM
Oct-20-25 11:08PM
Oct-10-25 10:06AM
Oct-09-25 09:25AM
Sep-15-25 09:09AM
Sep-10-25 09:51AM
Aug-17-25 11:41PM
Aug-07-25 04:01PM
Aug-05-25 04:05PM
(Business Wire)
+6.65%
-5.18%
Jul-24-25 04:05PM
Jul-17-25 04:30PM
Jul-12-25 09:40AM
Jul-11-25 09:38AM
Jun-24-25 05:42PM
May-15-25 08:00AM
May-08-25 04:01PM
May-06-25 05:30AM
(Clinical Trials Arena)
-14.27%
May-05-25 10:10AM
08:30AM
07:58AM
Apr-07-25 05:14PM
Apr-05-25 08:14AM
Mar-28-25 10:36AM
Mar-26-25 09:40PM
Mar-25-25 10:45AM
Mar-20-25 04:43PM
09:05AM
Mar-14-25 06:17PM
12:15PM
Mar-05-25 06:53PM
Mar-01-25 10:00AM
Feb-27-25 04:01PM
Feb-24-25 01:07PM
Jan-24-25 04:01PM
Dec-06-24 07:43PM
Dec-04-24 11:12PM
06:23PM
Dec-03-24 04:07PM
(Investor's Business Daily)
+48.98%
04:01PM
11:58AM
11:20AM
10:01AM
09:02AM
(Investor's Business Daily)
06:13AM
Dec-02-24 04:30PM
Nov-25-24 09:00AM
Nov-23-24 06:21AM
Nov-15-24 08:34PM
Nov-06-24 04:01PM
Nov-01-24 06:33PM
Oct-23-24 09:05PM
Oct-22-24 09:07PM
Oct-07-24 05:08PM
Sep-26-24 07:30PM
Sep-20-24 06:39PM
Sep-17-24 01:30AM
Sep-14-24 07:33PM
Sep-13-24 06:10AM
Aug-16-24 04:36PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Campbell David Alan President and CEO Jul 08 '26 Option Exercise 4.21 7,000 29,470 388,582 Jul 10 08:00 PM Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr Jun 02 '26 Sale 14.03 4,059 56,944 75,941 Jun 04 08:00 PM Janeen Noel Doyle Officer Jun 02 '26 Proposed Sale 14.03 4,059 56,944 Jun 02 06:03 PM Dobek Maria Vice President, Accounting May 11 '26 Sale 14.17 2,038 28,878 32,270 May 13 08:00 PM ANDY MEYER Former Affiliate Apr 13 '26 Proposed Sale 15.05 1,877 28,246 Apr 13 04:05 PM ZACHARIAH A MCIVER Former Officer Apr 02 '26 Proposed Sale 14.65 74,802 1,095,761 Apr 02 04:02 PM ANDY MEYER Former Affiliate Jan 26 '26 Proposed Sale 14.55 178,767 2,601,113 Jan 26 04:20 PM ANDY MEYER Former Affiliate Jan 23 '26 Proposed Sale 14.72 118,122 1,738,390 Jan 23 04:08 PM Meyer Andrew Hollman Chief Business Officer Jan 02 '26 Sale 13.73 1,879 25,799 83,095 Jan 02 09:00 PM DiRaimondo Thomas Chief Scientific Officer Jan 02 '26 Sale 13.73 2,505 34,394 124,425 Jan 02 09:00 PM Campbell David Alan President and CEO Jan 02 '26 Sale 13.73 8,072 110,829 284,982 Jan 02 09:00 PM Winter Charles M. Chief Technical Officer Jan 02 '26 Sale 13.73 2,401 32,966 77,721 Jan 02 09:00 PM McIver Zachariah Chief Medical Officer Jan 02 '26 Sale 13.73 2,714 37,263 23,286 Jan 02 09:00 PM Dobek Maria Vice President, Accounting Jan 02 '26 Sale 13.73 1,462 20,073 15,373 Jan 02 09:00 PM BYRON C ROBINSON Officer Dec 15 '25 Proposed Sale 15.50 16,666 258,366 Dec 15 04:06 PM BYRON C ROBINSON Officer Dec 08 '25 Proposed Sale 16.52 50,000 826,000 Dec 08 04:42 PM Meyer Andrew Hollman Chief Business Officer Dec 01 '25 Option Exercise 10.59 3,333 35,296 88,307 Dec 03 08:00 PM Meyer Andrew Hollman Chief Business Officer Dec 01 '25 Sale 32.98 3,333 109,929 84,974 Dec 03 08:00 PM BYRON C ROBINSON Officer Dec 02 '25 Proposed Sale 16.38 63,125 1,033,743 Dec 02 05:15 PM ANDREW MEYER Officer Dec 01 '25 Proposed Sale 34.09 3,333 113,622 Dec 01 04:20 PM
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.
President Dr. David Alan Campbell Ph.D.
Chief Scientific Officer Dr. Thomas Diraimondo Ph.D.
Chief Corporate & Business Development Officer Ms. Janeen Doyle
Vice President of Finance Mr. Matt Whitmire
Vice President of Accounting Ms. Maria Dobek